O-DSMT Stats & Data

O-DSMT is the main active metabolite (M1) of tramadol with much higher μ‑opioid receptor affinity than the parent drug; its effects are therefore more purely opioid-like and less serotonergic than tramadol, but potency and response vary widely across individuals. Community and forensic reports show that unregulated opioid products can be adulterated with potent synthetic opioids (e.g., nitazenes) or benzodiazepines; use drug-checking services where available and treat unknown powders/pills as potentially stronger than expected. Avoid polydrug use with CNS depressants (alcohol, benzodiazepines, gabapentinoids, barbiturates, Z‑drugs, GHB/GBL): these combinations are a leading cause of fatal opioid overdoses due to synergistic respiratory depression. DXM with opioids is flagged as dangerous in harm‑reduction guidance; avoid this mix. Although O‑DSMT lacks tramadol’s marked serotonin reuptake inhibition, mixing with serotonergic agents (e.g., MAOIs, SSRIs/SNRIs, linezolid, MDMA) still warrants caution because product mislabeling/adulteration and individual pharmacodynamics vary. Insufflation accelerates onset and can encourage redosing; this raises stacking/overdose risk—measure doses precisely, avoid frequent redoses, and wait through the peak before considering more. Seizures have been reported anecdotally with O‑DSMT—risk increases with stimulant use, sleep deprivation, high doses, or benzodiazepine withdrawal; avoid these conditions and keep doses conservative. Carry naloxone and ensure people around you know how to use it; naloxone may need repeat dosing and emergency services should always be called—place the person in the recovery position and monitor breathing. If injecting any drug, use new sterile equipment every time and never share; however, IV/IM use of O‑DSMT is strongly discouraged due to solubility uncertainties, particulate/excipient risks, and high overdose potential. Avoid using alone; if you do, consider remote supervision (e.g., phone/video) and set check‑ins. To reduce dependence risks, avoid multi‑day runs; tolerance and withdrawal (restless legs, insomnia, flu‑like symptoms, dysphoria) can emerge after just several days of heavy use—space sessions and plan breaks. Because human pharmacokinetic data are limited and supply is variable, treat published dosing/onset ranges as rough guides only.